Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Non Operating Income (2016 - 2025)

China Pharma Holdings filings provide 15 years of Non Operating Income readings, the most recent being -$21940.0 for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 22.74% to -$21940.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $51522.0, a 134.93% increase, with the full-year FY2025 number at $51522.0, up 134.93% from a year prior.
  • Non Operating Income hit -$21940.0 in Q4 2025 for China Pharma Holdings, up from -$23337.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $123753.0 in Q2 2025 to a low of -$332029.0 in Q4 2021.
  • Median Non Operating Income over the past 5 years was -$64161.5 (2021), compared with a mean of -$69290.2.
  • Biggest five-year swings in Non Operating Income: crashed 208.77% in 2021 and later soared 365.51% in 2025.
  • China Pharma Holdings' Non Operating Income stood at -$332029.0 in 2021, then surged by 71.34% to -$95172.0 in 2022, then skyrocketed by 49.86% to -$47722.0 in 2023, then surged by 40.5% to -$28396.0 in 2024, then increased by 22.74% to -$21940.0 in 2025.
  • The last three reported values for Non Operating Income were -$21940.0 (Q4 2025), -$23337.0 (Q3 2025), and $123753.0 (Q2 2025) per Business Quant data.